Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis

Zhe Wei Wei, Guang Kai Xia, Ying Wu, Roderich E. Schwarz, David D. Smith, Yu Long He, Chang Hua Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims: Effects and indications of no. 12b and 12p nodes dissection for gastric cancer are not determined yet. Here we retrospectively evaluated the effector no. 12b and 12p nodes dissection for treatment of lower third gastric cancer (LTGC). Methodology: Between 2001 and 2010, 110 LTGC patients with no. 12b and 12p nodes dissection (SHDL group) and 138 patients without no. 12b and 12p nodes dissection (non-SHDL group) were enrolled in this study. Clinicopathological features and prognostic data were compared between the two groups. Results: The nodal metastatic rate was 8.2% of no. 12b and 10.9% of no. 12p. The 5-year survival rate was 62.9% in the SHDL group and 51.4% in the non-SHDL group (p=0.16). Multivariate analysis with and without propensity score adjustment showed that SHDL was a significantly prognostic factor. The hazard ratio for death after D2 surgery plus SHDL was 0.457 (95% CI: 0.25 to 0.821; p=0.0085) compared to D2 surgery alone. More patients in the non-SHDL group had only lymph node recurrence compared to the SHDL group (4.3% vs. 0%, p=0.035). Conclusions: Skeletonization of the hepatoduodenal ligament is associated with superior outcomes for LTGC patients especially for those with involved local hepatoduodenal nodes.

Original languageEnglish (US)
Pages (from-to)1789-1796
Number of pages8
JournalHepato-Gastroenterology
Volume60
Issue number127
DOIs
StatePublished - Oct 2013

Fingerprint

Propensity Score
Ligaments
Stomach Neoplasms
Dissection
Multivariate Analysis
Survival Rate
Lymph Nodes
Recurrence
Therapeutics

Keywords

  • Gastric cancer
  • Hepatoduodenal ligament
  • Lymphadenectomy
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Wei, Z. W., Xia, G. K., Wu, Y., Schwarz, R. E., Smith, D. D., He, Y. L., & Zhang, C. H. (2013). Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. Hepato-Gastroenterology, 60(127), 1789-1796. https://doi.org/10.5754/hge13273

Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. / Wei, Zhe Wei; Xia, Guang Kai; Wu, Ying; Schwarz, Roderich E.; Smith, David D.; He, Yu Long; Zhang, Chang Hua.

In: Hepato-Gastroenterology, Vol. 60, No. 127, 10.2013, p. 1789-1796.

Research output: Contribution to journalArticle

Wei, Zhe Wei ; Xia, Guang Kai ; Wu, Ying ; Schwarz, Roderich E. ; Smith, David D. ; He, Yu Long ; Zhang, Chang Hua. / Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. In: Hepato-Gastroenterology. 2013 ; Vol. 60, No. 127. pp. 1789-1796.
@article{42615c71099d40328d39d7d897a9318e,
title = "Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis",
abstract = "Background/Aims: Effects and indications of no. 12b and 12p nodes dissection for gastric cancer are not determined yet. Here we retrospectively evaluated the effector no. 12b and 12p nodes dissection for treatment of lower third gastric cancer (LTGC). Methodology: Between 2001 and 2010, 110 LTGC patients with no. 12b and 12p nodes dissection (SHDL group) and 138 patients without no. 12b and 12p nodes dissection (non-SHDL group) were enrolled in this study. Clinicopathological features and prognostic data were compared between the two groups. Results: The nodal metastatic rate was 8.2{\%} of no. 12b and 10.9{\%} of no. 12p. The 5-year survival rate was 62.9{\%} in the SHDL group and 51.4{\%} in the non-SHDL group (p=0.16). Multivariate analysis with and without propensity score adjustment showed that SHDL was a significantly prognostic factor. The hazard ratio for death after D2 surgery plus SHDL was 0.457 (95{\%} CI: 0.25 to 0.821; p=0.0085) compared to D2 surgery alone. More patients in the non-SHDL group had only lymph node recurrence compared to the SHDL group (4.3{\%} vs. 0{\%}, p=0.035). Conclusions: Skeletonization of the hepatoduodenal ligament is associated with superior outcomes for LTGC patients especially for those with involved local hepatoduodenal nodes.",
keywords = "Gastric cancer, Hepatoduodenal ligament, Lymphadenectomy, Prognosis",
author = "Wei, {Zhe Wei} and Xia, {Guang Kai} and Ying Wu and Schwarz, {Roderich E.} and Smith, {David D.} and He, {Yu Long} and Zhang, {Chang Hua}",
year = "2013",
month = "10",
doi = "10.5754/hge13273",
language = "English (US)",
volume = "60",
pages = "1789--1796",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "127",

}

TY - JOUR

T1 - Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis

AU - Wei, Zhe Wei

AU - Xia, Guang Kai

AU - Wu, Ying

AU - Schwarz, Roderich E.

AU - Smith, David D.

AU - He, Yu Long

AU - Zhang, Chang Hua

PY - 2013/10

Y1 - 2013/10

N2 - Background/Aims: Effects and indications of no. 12b and 12p nodes dissection for gastric cancer are not determined yet. Here we retrospectively evaluated the effector no. 12b and 12p nodes dissection for treatment of lower third gastric cancer (LTGC). Methodology: Between 2001 and 2010, 110 LTGC patients with no. 12b and 12p nodes dissection (SHDL group) and 138 patients without no. 12b and 12p nodes dissection (non-SHDL group) were enrolled in this study. Clinicopathological features and prognostic data were compared between the two groups. Results: The nodal metastatic rate was 8.2% of no. 12b and 10.9% of no. 12p. The 5-year survival rate was 62.9% in the SHDL group and 51.4% in the non-SHDL group (p=0.16). Multivariate analysis with and without propensity score adjustment showed that SHDL was a significantly prognostic factor. The hazard ratio for death after D2 surgery plus SHDL was 0.457 (95% CI: 0.25 to 0.821; p=0.0085) compared to D2 surgery alone. More patients in the non-SHDL group had only lymph node recurrence compared to the SHDL group (4.3% vs. 0%, p=0.035). Conclusions: Skeletonization of the hepatoduodenal ligament is associated with superior outcomes for LTGC patients especially for those with involved local hepatoduodenal nodes.

AB - Background/Aims: Effects and indications of no. 12b and 12p nodes dissection for gastric cancer are not determined yet. Here we retrospectively evaluated the effector no. 12b and 12p nodes dissection for treatment of lower third gastric cancer (LTGC). Methodology: Between 2001 and 2010, 110 LTGC patients with no. 12b and 12p nodes dissection (SHDL group) and 138 patients without no. 12b and 12p nodes dissection (non-SHDL group) were enrolled in this study. Clinicopathological features and prognostic data were compared between the two groups. Results: The nodal metastatic rate was 8.2% of no. 12b and 10.9% of no. 12p. The 5-year survival rate was 62.9% in the SHDL group and 51.4% in the non-SHDL group (p=0.16). Multivariate analysis with and without propensity score adjustment showed that SHDL was a significantly prognostic factor. The hazard ratio for death after D2 surgery plus SHDL was 0.457 (95% CI: 0.25 to 0.821; p=0.0085) compared to D2 surgery alone. More patients in the non-SHDL group had only lymph node recurrence compared to the SHDL group (4.3% vs. 0%, p=0.035). Conclusions: Skeletonization of the hepatoduodenal ligament is associated with superior outcomes for LTGC patients especially for those with involved local hepatoduodenal nodes.

KW - Gastric cancer

KW - Hepatoduodenal ligament

KW - Lymphadenectomy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84893945121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893945121&partnerID=8YFLogxK

U2 - 10.5754/hge13273

DO - 10.5754/hge13273

M3 - Article

C2 - 24624453

AN - SCOPUS:84893945121

VL - 60

SP - 1789

EP - 1796

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 127

ER -